Damian Garde

Biography for Damian Garde

Damian Garde, Editor

Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at dgarde@fiercemarkets.com and follow @DamianFierce on Twitter.

Articles by Damian Garde

Allergan blueprints a big Texas expansion amid battle with spendthrift Valeant

Allergan has signed a lease for big chunk of office space in Texas, according to the Austin Business Journal, keeping quiet on its plans as it slashes jobs around the globe.

Biotech backer LSP banks $100M to fund a new generation of startups

European venture outfit LSP (Life Sciences Partners) has raised $100 million toward a new biotech fund, setting out to stake a dozen or so innovators in drugs, devices and diagnostics.

Portola's 'breakthrough' anti-anticoagulant clears a Phase III hurdle

Portola Pharmaceuticals' antidote to Big Pharma's latest crop of blockbuster blood thinners hit the mark in its first Phase III trial, clearing the way for an FDA submission next year.

FibroGen lines up a $125M IPO to shoulder its way into the IPF race

Flush with cash from its high-profile collaborators, FibroGen is plotting a $120 million IPO to help bankroll a stable of unpartnered drugs, including a promising lung treatment with huge market potential.

GlaxoSmithKline deepens its commitment to 'electroceuticals'

GlaxoSmithKline is expanding its efforts to encourage research into bioelectronic medicine, putting up $5 million to support R&D projects around the world.

J&J makes a splash in hep C with a $1.75B deal for Alios

Johnson & Johnson is taking a deep dive into antivirals, trading $1.75 billion for private biotech Alios BioPharma to get its hands on a midstage treatment and some early assets that could expand its share of the blockbuster hepatitis C market.

Regeneron's would-be blockbuster completes the allergic circle with Phase II success

Regeneron and partner Sanofi have notched another midstage milestone with their in-development allergy drug, a victory that affirms the hypothesis behind a treatment the companies believe could bring in billions.

Catalyst soars as its controversial rare disease drug aces Phase III

Catalyst Pharmaceutical Partners is heralding positive late-stage results for its lead drug, planning to make its case to the FDA in hopes of winning approval for a much-scrutinized orphan treatment.

Bristol-Myers' oncology star lines up for lung cancer approval, leading the PD-1 pack

Among the scrum of drugmakers racing forward with a new class of cancer treatments, Bristol-Myers Squibb was the first to win a global regulatory nod and is now first in line for approval in lung cancer, a particularly lucrative indication for the group of promising oncology drugs.

Alimera and pSivida finally win FDA approval for thrice-rejected drug

After a series of painful rejections, partners Alimera Sciences and pSivida have finally convinced the FDA to approve the eye drug Iluvien, sending each company's shares roaring on some renewed optimism for the long-delayed treatment.